Myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) is a complex, poorly understood condition characterised by post-exertional malaise, cognitive dysfunction, sleep disturbance, and profound fatigue. A growing body of research suggests mitochondrial dysfunction and abnormal energy metabolism may play a central role.

Several research groups have identified elevated blood lactate levels and impaired oxidative phosphorylation in ME/CFS patients — particularly following exertion. This metabolic pattern resembles the Warburg effect seen in cancer cells: a shift away from efficient mitochondrial energy production toward less efficient anaerobic glycolysis.

DCA’s mechanism of action — inhibiting PDK and reactivating pyruvate dehydrogenase — targets exactly this dysfunction. By pushing cells back toward mitochondrial metabolism, DCA theoretically addresses one of the proposed core metabolic abnormalities in ME/CFS.

Published human data on DCA specifically for ME/CFS is extremely limited. Most evidence comes from case reports and small observational series. No large randomised controlled trial has been conducted. What exists is a plausible mechanistic rationale and a small number of reported cases.

This is an area of active research interest. The ME/CFS research community has increasingly focused on metabolic and mitochondrial interventions, and DCA represents one candidate worth formal investigation.

This article is for informational and educational purposes only. AuraDCA products are intended for research use only.